Aurobindo Pharma’s subsidiary, A1 Biochem USA, has acquired A1 Biochem Labs LLC for USD 15.247 million. This strategic move aims to launch a dedicated Contract Research, Development, and Manufacturing (CRDMO) platform, signaling the company's expansion into specialized API services. While the deal is small relative to Aurobindo’s scale, it serves as a entry point into the lucrative high-end research services market.
Aurobindo Pharma Expands into CRDMO with US Lab Acquisition
Aurobindo Pharma has acquired 100% of A1 Biochem Labs LLC for USD 15.247 million.
This transaction was completed by its step-down subsidiary, A1 Biochem USA, on October 2, 2026.
Reader Takeaway: Aurobindo enters the CRDMO space to capture long-cycle contracts; watch for integration success and future revenue scale.
What just happened
Aurobindo Pharma has finalized the acquisition of the North Carolina-based A1 Biochem Labs LLC. The deal, valued at approximately USD 15.25 million, marks the company's entry into the specialized Contract Research, Development, and Manufacturing (CRDMO) sector. The target company operates a scientific laboratory in Wilmington and has been incorporated since 2015.
Why this matters
This acquisition is a strategic pivot for Aurobindo Pharma as it looks to diversify its revenue streams beyond generic manufacturing. By acquiring the front-end research capabilities of A1 Labs, Aurobindo aims to transition from a pure API supplier to a full-service partner for global pharmaceutical clients. This is expected to facilitate deeper, longer-cycle relationships with customers, potentially improving margins over time.
Governance and Transaction Details
The deal was classified as a related party transaction as the seller, Dr. Rajendra Gadikota, is a director at A1 Labs India. However, Aurobindo Pharma has clarified that the acquisition was executed on an arm's length basis and confirmed that its promoter group holds no interest in the entity. Dr. Gadikota will remain with the company post-acquisition, ensuring continuity in R&D operations.
Context Metrics
A1 Labs LLC reported revenues of USD 6.35 million in 2023, USD 9.23 million in 2024, and USD 5.92 million in 2025. These figures demonstrate the target's current operational size, which remains modest compared to Aurobindo's consolidated global revenue.
What to track next
Investors should monitor the company's ability to leverage this new CRDMO platform to secure complex, high-value contracts. Success will depend on the integration of A1 Labs’ research talent with Aurobindo’s existing global manufacturing infrastructure.